Streetbeat News

Analyst Ratings

ABNB

Airbnb (NASDAQ:ABNB) has been reviewed by 13 analysts in the last three months, showing a mix of ratings from bullish to bearish. The average 12-month price target is $131.62, down from the previous $137.20. Analysts have adjusted their ratings and price targets, with some maintaining and others raising or lowering their stance. Airbnb's financial performance shows strong revenue growth, net margin, ROE, and ROA, with prudent debt management. The company's market cap indicates a strong market position.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:01 pm

ZIM

Five financial analysts have recently updated their ratings on ZIM Integrated Shipping (NYSE:ZIM), with a mix of bullish, indifferent, and bearish sentiments. The average 12-month price target is now $9.94, down from $10.28, with a high estimate of $20.00 and a low of $5.00. Analysts from Jefferies, B of A Securities, Barclays, and JP Morgan have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. ZIM's financials show a significant revenue decline, poor net margin, low ROE and ROA, and a high debt-to-equity ratio, suggesting challenges ahead.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:00 pm

AMRX

Barclays analyst Balaji Prasad has maintained an Overweight rating on Amneal Pharmaceuticals (NASDAQ:AMRX) and increased the price target from $6 to $8.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 12:00 pm

CCCC

Analysts have mixed views on C4 Therapeutics (NASDAQ:CCCC), with recent ratings ranging from bullish to indifferent. The average 12-month price target is now $8.4, down from $10.00, indicating a 16.0% decrease. Analysts from JP Morgan, Stifel, Morgan Stanley, BMO Capital, and HC Wainwright & Co. have made various adjustments to their ratings and price targets. C4 Therapeutics is a biopharmaceutical company with a market cap above industry averages, a revenue growth rate of 63.93%, and strong profitability indicators like net margin and ROE, but a higher debt-to-equity ratio than the industry average.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:00 pm

FLYW

Flywire (NASDAQ:FLYW) has been the subject of diverse analyst ratings over the past three months, with 12 analysts offering varying opinions. The recent trend shows a shift towards a more cautious stance, with several analysts lowering their price targets. The average 12-month price target is now $33.17, down from $37.38. Despite this, Flywire's financial performance remains strong, with notable revenue growth and a solid net margin, although its ROE is below industry averages. The company's market capitalization is smaller compared to industry peers, and it has a conservative financial approach with a debt-to-equity ratio of 0.0.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:00 pm

ZI

B of A Securities analyst Koji Ikeda has upgraded ZoomInfo Technologies (NASDAQ:ZI) from Neutral to Buy and increased the price target from $20 to $25.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 12:00 pm

GMAB

Genmab (NASDAQ:GMAB) has received diverse analyst ratings in the last three months, with 5 analysts offering views ranging from bullish to somewhat bearish. The average 12-month price target is $45.8, with a high of $50.00 and a low of $32.00, reflecting a 3.32% increase from the previous average of $44.33. Analyst Raghuram Selvaraju from HC Wainwright & Co. has adjusted his price target and maintained a 'Buy' rating, while Matthew Harrison from Morgan Stanley has lowered his rating to 'Underweight' with a price target of $32.00. Genmab, a biotech company specializing in antibody therapeutics, has shown a revenue growth rate of 16.08% and a high net margin of 44.88%, but its revenue growth lags behind industry peers. The company's financial health is strong, with an ROE of 7.11% and an ROA of 6.33%, and a low debt-to-equity ratio of 0.03.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:00 pm

DT

Needham analyst Mike Cikos reaffirmed a Buy rating on Dynatrace (NYSE:DT) and increased the price target from $60 to $70, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:57 am

AAL

Citigroup analyst Stephen Trent upgraded American Airlines Group (AAL) from Neutral to Buy and increased the price target from $14 to $20.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:54 am

RPD

UBS analyst Roger Boyd has upgraded Rapid7 (NASDAQ:RPD) from Neutral to Buy and increased the price target from $53 to $70, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:53 am